Morning Briefing
Summaries of health policy coverage from major news organizations
Generic Drug Delays Cost U.S. Payers Millions
Problems surrounding an Indian company's launch of generic versions of three blockbuster drugs have preserved millions in revenue for the brand-name makers, reports The Wall Street Journal. Meanwhile, Swiss pharmaceutical giant Novartis projects its overhaul will boost profits, and the impact of a $1,000-a-pill drug to treat hepatitis C is examined.
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
